Stock MIST MILESTONE PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Milestone Pharmaceuticals Inc.

Equities

MIST

CA59935V1076

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.54 USD -2.53% Intraday chart for Milestone Pharmaceuticals Inc. -6.10% -7.78%
Apr. 08 Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting CI
Mar. 28 Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting CI
Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA MT
Milestone Pharmaceuticals Inc. Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia CI
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Piper Sandler Trims Price Target on Milestone Pharmaceuticals to $5 From $6, Keeps Overweight Rating MT
Milestone Pharma Shares Rise 25% After Plans to Resubmit Etripamil NDA DJ
Milestone Pharmaceuticals Inc. Announces Plan to Resubmit NDA for Etripamil for the Treatment of Psvt CI
TD Cowen Cuts Price Target on Milestone Pharmaceuticals to $9 From $17, Maintains Outperform Rating MT
Milestone Pharmaceuticals Says FDA Issued Refusal-to-File Letter for New Drug Application for Etripamil; Shares Fall Pre-Bell MT
Milestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDA DJ
Top Premarket Decliners MT
Milestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File Letter DJ
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT CI
Transcript : Milestone Pharmaceuticals Inc. - Shareholder/Analyst Call
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Alta Advisers Sends a Letter to Milestone Pharmaceuticals CI
Milestone Pharmaceuticals Inc. Announces Submission of New Drug Application to the U.S. FDA for Etripamil CI
Oppenheimer Adjusts Milestone Pharmaceuticals Price Target to $11 From $13, Maintains Outperform Rating MT
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Top Premarket Decliners MT
Jefferies Downgrades Milestone Pharmaceuticals to Hold From Buy MT
Milestone Pharmaceuticals Inc. Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in the Lancet CI
Transcript : Milestone Pharmaceuticals Inc. - Special Call
Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Chart Milestone Pharmaceuticals Inc.

Chart Milestone Pharmaceuticals Inc.
More charts

Company Profile

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Sector
Biotechnology & Medical Research
Calendar
2024-05-14 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.54 USD
Average target price
10.5 USD
Spread / Average Target
+581.82%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MILESTONE PHARMACEUTICALS INC. Stock Milestone Pharmaceuticals Inc.
-7.78% 96.6M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MIST Stock
  4. News Milestone Pharmaceuticals Inc.
  5. Top Premarket Decliners